3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Breast
4
Genitourinary
3
Thoracic
2
Sarcoma
2
Lymphoid
2
Gynecologic
2
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Head & Neck
1
Endocrine
1
Dermatologic
1
Classical hematology
1
CNS
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Fluorodeoxyglucose F18
3
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
tivozanib
1
romidepsin
1
pembrolizumab
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
atezolizumab
1
alectinib
1
aldesleukin
1
Specimen Handling
1
Quality of Life
1
Patient Reported Outcome Measures
1
Neuropsychological Tests
1
Molecular Diagnostic Techniques
1
Lactones
1
Interleukin-13
1
Immunotherapy
1
FAPI-46
1
Drug Therapy
1
Depsipeptides
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
entrectinib
×
NET
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA